Premium
Fecal microbiota transplantation for the treatment of Clostridium difficile infection
Author(s) -
Rao Krishna,
Safdar Nasia
Publication year - 2016
Publication title -
journal of hospital medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.128
H-Index - 65
eISSN - 1553-5606
pISSN - 1553-5592
DOI - 10.1002/jhm.2449
Subject(s) - fecal bacteriotherapy , clostridium difficile , medicine , clostridium infections , feces , microbiology and biotechnology , transplantation , c difficile , intensive care medicine , antibiotics , biology
Clostridium difficile , a major cause of healthcare‐associated diarrhea due to perturbation of the normal gastrointestinal microbiome, is responsible for significant morbidity, mortality, and healthcare expenditures. The incidence and severity of C difficile infection (CDI) is increasing, and recurrent disease is common. Recurrent infection can be difficult to manage with conventional antibiotic therapy. Fecal microbiota transplantation (FMT), which involves instillation of stool from a healthy donor into the gastrointestinal tract of the patient, restores the gut microbiome to a healthy state. FMT has emerged as a promising new treatment for CDI. There are limited data on FMT for treatment of primary CDI, but FMT appears safe and effective for recurrent CDI. The safety and efficacy of FMT in patients with severe primary or severe recurrent CDI has not been established. Patients with inflammatory bowel disease (IBD) who undergo FMT for CDI may be at increased risk of IBD flare, and caution should be exercised with use of FMT in that population. The long‐term safety of FMT is unknown; thus, rigorously conducted prospective studies are needed. Journal of Hospital Medicine 2016;11:56–61. © 2015 Society of Hospital Medicine